



Pantomics, Inc.

Advancing Biomedical Science Through Tissue Arrays

Phone: 415-863-2380
Support: info@pantomics.com
Web: www.pantomics.com

Cat No: EMC1502 - Endometrial cancer tissue array

Lot#	Cores	Size	Cut	Format	QA/QC	Image
EMC150201	150	1.1mm	4um	10X15	H&E, IHC anti-Cytokeratin	

Recommended applications: For Research use only. RNA or protein endometrium cancer/non-tumor tissue profiling using IHC or ISH; Antibody characterization.

Description: Endometrial cancer tissue array with progressive changes, 150 cores, non-overlapping with EMC1501, including 23 cases of normal, 7 cases of hyperplasia and 45 cases of duplicated neoplastic tissues of the endometrium.

All the tissues were from surgical resection. They were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They can be stored for use at 4C for up to six months from the date of shipment. **There may be 5 to 10% of tissue core loss.**

Array Position	Sex	Age	Anatomic Site	Pathology	Grade	Stage
A01	F	40	Uterus, endometrium	Hyperplasia	null	null
A02	F	48	Uterus, endometrium	Hyperplasia	null	null
A03	F	53	Uterus, endometrium	Hyperplasia	null	null
A04	F	46	Uterus, endometrium	Hyperplasia	null	null
A05	F	47	Uterus, endometrium	Hyperplasia	null	null
A06	F	44	Uterus, endometrium	Hyperplasia	null	null
A07	F	43	Uterus, endometrium	Hyperplasia	null	null
A08	F	57	Uterus, endometrium	Normal, proliferative phase	null	null
A09	F	44	Uterus, endometrium	Normal, proliferative phase	null	null
A10	F	46	Uterus, endometrium	Normal, proliferative phase	null	null
A11	F	57	Uterus, endometrium	Normal, proliferative phase	null	null
A12	F	44	Uterus, endometrium	Normal, proliferative phase	null	null
A13	F	46	Uterus, endometrium	Normal, proliferative phase	null	null
A14	F	52	Uterus, endometrium	Normal, proliferative phase	null	null
A15	F	45	Uterus, endometrium	Normal, proliferative phase	null	null
B01	F	48	Uterus, endometrium	Normal, proliferative phase	null	null
B02	F	46	Uterus, endometrium	Normal, proliferative phase	null	null
B03	F	36	Uterus, endometrium	Normal, proliferative phase	null	null
B04	F	58	Uterus, endometrium	Normal, proliferative phase	null	null
B05	F	52	Uterus, endometrium	Normal, proliferative phase	null	null
B06	F	43	Uterus, endometrium	Normal, proliferative phase	null	null
B07	F	46	Uterus, endometrium	Normal, proliferative phase	null	null
B08	F	43	Uterus, endometrium	Normal, proliferative phase	null	null
B09	F	45	Uterus, endometrium	Normal, proliferative phase	null	null
B10	F	43	Uterus, endometrium	Normal, proliferative phase	null	null
B11	F	47	Uterus, endometrium	Normal, proliferative phase	null	null
B12	F	31	Uterus, endometrium	Normal, proliferative phase	null	null
B13	F	39	Uterus, endometrium	Normal, secretory phase	null	null
B14	F	49	Uterus, endometrium	Normal, secretory phase	null	null
B15	F	46	Uterus, endometrium	Normal, secretory phase	null	null
C01	F	42	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C02	F	65	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C03	F	34	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C04	F	44	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C05	F	50	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C06	F	42	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C07	F	64	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C08	F	45	Uterus, endometrium	Adenocarcinoma	I	T1N0M0
C09	F	61	Uterus, endometrium	Adenocarcinoma	I	T1N0M0



Pantomics, Inc.

Phone: 415-863-2380
Support: info@pantomics.com
Web: www.pantomics.com

Advancing Biomedical Science Through Tissue Arrays

C10	F	56	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
C11	F	41	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
C12	F	56	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
C13	F	38	Uterus, endometrium	Adenocarcinoma	I	T2NOMO
C14	F	58	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
C15	F	54	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D01	F	42	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D02	F	65	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D03	F	34	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D04	F	44	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D05	F	50	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D06	F	42	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D07	F	64	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D08	F	45	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D09	F	61	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D10	F	56	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D11	F	41	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D12	F	56	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D13	F	38	Uterus, endometrium	Adenocarcinoma	I	T2NOMO
D14	F	58	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
D15	F	54	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E01	F	55	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E02	F	52	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E03	F	71	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E04	F	44	Uterus, endometrium	Adenocarcinoma	I	T2NOMO
E05	F	38	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E06	F	50	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E07	F	43	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E08	F	49	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
E09	F	56	Uterus, endometrium	Adenocarcinoma	I~II	T1N1MO
E10	F	46	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
E11	F	67	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
E12	F	45	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
E13	F	69	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
E14	F	40	Uterus, endometrium	Adenocarcinoma	I~II	T2N1MO
E15	F	58	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
F01	F	55	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F02	F	52	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F03	F	71	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F04	F	44	Uterus, endometrium	Adenocarcinoma	I	T2NOMO
F05	F	38	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F06	F	50	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F07	F	43	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F08	F	49	Uterus, endometrium	Adenocarcinoma	I	T1NOMO
F09	F	56	Uterus, endometrium	Adenocarcinoma	I~II	T1N1MO
F10	F	46	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
F11	F	67	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
F12	F	45	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
F13	F	69	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
F14	F	40	Uterus, endometrium	Adenocarcinoma	I~II	T2N1MO
F15	F	58	Uterus, endometrium	Adenocarcinoma	I~II	T1NOMO
G01	F	69	Uterus, endometrium	Adenocarcinoma	II	T1NOMO
G02	F	48	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G03	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G04	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G05	F	57	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G06	F	29	Uterus, endometrium	Adenocarcinoma	II~III	T2N1MO
G07	F	44	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G08	F	55	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G09	F	41	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO
G10	F	51	Uterus, endometrium	Adenocarcinoma	II~III	T1NOMO



Pantomics, Inc.

Phone: 415-863-2380
 Support: info@pantomics.com
 Web: www.pantomics.com

Advancing Biomedical Science Through Tissue Arrays

G11	F	84	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
G12	F	53	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
G13	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T4N1M0
G14	F	52	Uterus, endometrium	Adenocarcinoma	III	T2N1M0
G15	F	67	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
H01	F	69	Uterus, endometrium	Adenocarcinoma	II	T1N0MO
H02	F	48	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H03	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H04	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H05	F	57	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H06	F	29	Uterus, endometrium	Adenocarcinoma	II~III	T2N1M0
H07	F	44	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H08	F	55	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H09	F	41	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H10	F	51	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H11	F	84	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H12	F	53	Uterus, endometrium	Adenocarcinoma	II~III	T1N0MO
H13	F	52	Uterus, endometrium	Adenocarcinoma	II~III	T4N1M0
H14	F	52	Uterus, endometrium	Adenocarcinoma	III	T2N1M0
H15	F	67	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I01	F	69	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I02	F	56	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
I03	F	63	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
I04	F	54	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I05	F	56	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I06	F	45	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I07	F	56	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I08	F	80	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
I09	F	75	Uterus, endometrium	Adenocarcinoma	III	T1N1M0
I10	F	58	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
I11	F	53	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
I12	F	53	Uterus, endometrium	Adenocarcinoma	III	T3N0MO
I13	F	48	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I14	F	68	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
I15	F	64	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J01	F	69	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J02	F	56	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
J03	F	63	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
J04	F	54	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J05	F	56	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J06	F	45	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J07	F	56	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J08	F	80	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
J09	F	75	Uterus, endometrium	Adenocarcinoma	III	T1N1M0
J10	F	58	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
J11	F	53	Uterus, endometrium	Adenocarcinoma	III	T2N0MO
J12	F	53	Uterus, endometrium	Adenocarcinoma	III	T3N0MO
J13	F	48	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J14	F	68	Uterus, endometrium	Adenocarcinoma	III	T1N0MO
J15	F	64	Uterus, endometrium	Adenocarcinoma	III	T1N0MO

Notes: Bake at 60C for ~60 minutes before use. If antigen retrieving is needed, it is important to avoid **direct-boiling and high pH or high strength** antigen retrieving buffer. For availability of complimentary IHC data, please contact us at info@pantomics.com.

Certified by: Langxing Pan, M.D.



TNM Classification: Endometrium carcinoma

T - Primary tumor

TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
Tis - Carcinoma in situ (preinvasive carcinoma)
T1 - Tumor confined to corpus uteri
 T1a - Tumor limited to endometrium
 T1 b - Tumor invades up to less than one half of myometrium
 T1c - Tumor invades to more than one half of myometrium
T2 - Tumor invades cervix but does not extend beyond uterus
 T2a - Endocervical glandular involvement only
 T2b - Cervical stromal invasion
T3 (and/or N1) - Local or regional spread as specified below
 T3a - Tumor involve serosa and/or adnexa and/or cancer cells in ascites or peritoneal washing
 T3b - Vaginal involvement
 (N1) - Metastasis to pelvic and/or para-aortic lymph nodes
T4 - Tumor invades bladder mucosa and/or bowel mucosa

N - Regional lymph nodes

NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis N1 -
Regional lymph node metastasis
 N1a - Metastasis in a single regional lymph node
 N1b - Metastasis in multiple regional lymph nodes

M - Distant metastasis

MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis

TNM classification of malignant tumours, Fifth Edition (1997)

Comparison between TNM and FIGO

TNM category	FIGO Stage	TNM category	FIGO Stage
Tis	Jo	T3 and/or N1	III
T1	J1	T3a	IIIA
T1a	IA	T3b	IIIB
T1b	IB	N1	IIIC
T1c	1C	T4	IVA
T2	II	M1	IVB
T2a	IIA		
T2b	MB		